Incorporation of Butyryl-Lysine into Phage-Displayed Peptide Libraries.

Sophea Pa, Rutendo Nyamadzawo, Gopal Dubey, J Trae Hampton, Wenshe R Liu

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Phage Display as a Promising Platform for Peptide Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sophea PaTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.

Rutendo NyamadzawoTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.

Gopal DubeyTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA.

J Trae HamptonTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA. jhampton1@tamu.edu.

Wenshe R LiuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX, 77843, USA. wsliu2007@tamu.edu.

Funding

Use of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026

$2.6M

A Multiplatform Approach to Develop ENL-Targeting Molecules as Drug Candidates for Acute Myeloid LeukemiaR01CA291968 · NCI · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2024 to 2026

$2.4M

NCI NIH HHS R01 CA291968NIGMS NIH HHS R35 GM145351

6 · The paper itself

Abstract

There are several epigenetic reader proteins that recognize butyrylated lysine residues, yet the majority peptide probes have been limited to histone-based substrates. Development of selective peptide substrates will play a key role in studying these proteins and in developing inhibitors of therapeutic potential. We have previously reported a strategy to incorporate N

Indexed as

LysinePeptide LibraryEpigenesis, GeneticHumansPeptidesLysinePeptide LibraryPeptidesEpigenetic proteinsNε-butyryl-L-lysinePhage biopanningPhage displayYEATS domain

Identifiers

PMID42400832

DOI10.1007/978-1-0716-5249-7_1

PMCPMC13593374

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.